Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...